221 related articles for article (PubMed ID: 25809654)
1. [Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Klapper W; Kreipe H
Pathologe; 2015 Mar; 36(2):164-70. PubMed ID: 25809654
[TBL] [Abstract][Full Text] [Related]
2. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
3. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
[TBL] [Abstract][Full Text] [Related]
4. Disease-specific mutations in mature lymphoid neoplasms: recent advances.
Sakata-Yanagimoto M; Enami T; Yokoyama Y; Chiba S
Cancer Sci; 2014 Jun; 105(6):623-9. PubMed ID: 24689848
[TBL] [Abstract][Full Text] [Related]
5. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
6. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
7. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
8. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
[TBL] [Abstract][Full Text] [Related]
9. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
10. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
11. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutations in hairy-cell leukemia.
Pardanani A; Tefferi A
N Engl J Med; 2011 Sep; 365(10):961; author reply 961-2. PubMed ID: 21899462
[No Abstract] [Full Text] [Related]
13. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia.
Ping N; Wang Q; Wang Q; Dong S; Wu L; Xue Y; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2012 Dec; 53(12):2498-9. PubMed ID: 22639828
[No Abstract] [Full Text] [Related]
14. [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].
Hussein K; Büsche G; Schlue J; Lehmann U; Kreipe H
Pathologe; 2012 Nov; 33(6):508-17. PubMed ID: 23085694
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders.
Jajosky AN; Havens NP; Sadri N; Oduro KA; Moore EM; Beck RC; Meyerson HJ
Am J Clin Pathol; 2021 Aug; 156(3):433-444. PubMed ID: 33712839
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
Patel U; Luthra R; Medeiros LJ; Patel KP
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
18. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.
Swerdlow SH; Kuzu I; Dogan A; Dirnhofer S; Chan JK; Sander B; Ott G; Xerri L; Quintanilla-Martinez L; Campo E
Virchows Arch; 2016 Mar; 468(3):259-75. PubMed ID: 26454445
[TBL] [Abstract][Full Text] [Related]
19. Improved accuracy of discrimination between IgM multiple myeloma and Waldenström macroglobulinaemia by testing for MYD88 L265P mutations.
Willenbacher W; Willenbacher E; Brunner A; Manzl C
Br J Haematol; 2013 Jun; 161(6):902-4. PubMed ID: 23560587
[No Abstract] [Full Text] [Related]
20. CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
Xu X; Broome EH; Rashidi HH; South ST; Dell'aquila ML; Wang HY
Int J Clin Exp Pathol; 2010 Sep; 3(8):798-807. PubMed ID: 21151394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
